Reuters, 29 Jun 2009, Nopporn Wong-Anan
SINGAPORE, June 29 (Reuters) - The governments of Australia, New Zealand, Taiwan and Singapore have bought GlaxoSmithKline's (GSK.L) Relenza flu treatment since the H1N1 outbreak began in April, a top GSK official said on Monday.
GSK Asia Pacific director Christophe Weber told Reuters the firm had advised governments to keep the inhaled Relenza drug at 30-50 percent of their overall flu drug stockpiles, which mainly comprise the Tamiflu capsule made by competitor Roche.
Read More
